Tiziana Life Sciences Initiates Third Clinical Site for Phase 2 Trial of Intranasal Foralumab for Secondary Progressive Multiple Sclerosis
New York, April 2, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a pioneering biotechnology company specializing in the development of innovative immunomodulation therapies, announced the initiation of dosing at the Johns Hopkins University (JHU) Autoimmunity Center of Excellence, marking the third clinical site in its Phase 2 trial for intranasal foralumab as a potential treatment for non-active Secondary Progressive Multiple Sclerosis (na-SPMS).
About Tiziana Life Sciences and Intranasal Foralumab
Tiziana Life Sciences is a biotech company dedicated to creating groundbreaking immunomodulation therapies. Their lead development candidate, intranasal foralumab, is a fully human, anti-CD3 monoclonal antibody. This innovative treatment is administered intranasally, aiming to bypass the need for invasive injections or infusions. Intranasal foralumab is designed to target T cells, which play a crucial role in the immune response, and could potentially bring about significant improvements for individuals suffering from na-SPMS.
Phase 2 Trial Expansion
The Phase 2 trial, which commenced in late 2024, is being conducted at three leading clinical sites: JHU, Sheba Medical Center in Israel, and the University of Warwick in the United Kingdom. The trial’s primary objective is to assess the safety, tolerability, and efficacy of intranasal foralumab in patients with na-SPMS. The trial is expected to enroll approximately 60 patients, with each receiving the treatment intranasally twice a week for 24 weeks.
Impact on Individuals with SPMS
Secondary Progressive Multiple Sclerosis (SPMS) is a debilitating neurological condition characterized by a worsening of the symptoms experienced in the relapsing-remitting phase of MS. Currently, there is no approved treatment for the progressive phase of MS. If successful, intranasal foralumab could represent a significant breakthrough for the millions of people worldwide living with SPMS. By providing a non-invasive treatment option, Tiziana Life Sciences aims to improve the quality of life for those suffering from this condition.
Global Implications
The successful development and approval of intranasal foralumab could have profound implications for the global healthcare landscape. With an estimated 2.8 million people living with MS worldwide, a treatment for SPMS would significantly impact the lives of countless individuals and their families. Furthermore, the innovative intranasal administration method could pave the way for new treatments in various therapeutic areas, making healthcare more accessible and convenient for patients.
Conclusion
Tiziana Life Sciences’ initiation of dosing at the third clinical site for its Phase 2 trial of intranasal foralumab marks an essential step forward in the quest for a treatment for non-active Secondary Progressive Multiple Sclerosis. With the potential to provide a non-invasive, convenient, and effective solution for millions of people worldwide, intranasal foralumab represents a beacon of hope for the future of MS treatment. As the trial progresses, the global community eagerly awaits the results that could change the course of healthcare for those affected by this debilitating condition.
- Tiziana Life Sciences initiates dosing at the third clinical site for its Phase 2 trial of intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS).
- The trial is being conducted at three leading clinical sites: Johns Hopkins University (JHU), Sheba Medical Center in Israel, and the University of Warwick in the United Kingdom.
- Intranasal foralumab is a fully human, anti-CD3 monoclonal antibody designed to target T cells and could potentially bring about significant improvements for individuals suffering from na-SPMS.
- The successful development and approval of intranasal foralumab could have profound implications for the global healthcare landscape, impacting the lives of millions of people worldwide and potentially paving the way for new treatments in various therapeutic areas.
